Melanoma MRI: Difference between revisions
Jump to navigation
Jump to search
Varun Kumar (talk | contribs) (Created page with "{{Melanoma}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Types of cancer Category:Oncology Category:Dermatology {{WikiDoc...") |
No edit summary |
||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Melanoma}} | {{Melanoma}} | ||
{{CMG}} | {{CMG}} {{AE}} {{YD}}; {{SSK}} | ||
==Overview== | ==Overview== | ||
[[Magnetic resonance imaging|MRI]] can be useful in the [[Cancer staging|staging]] of [[brain]] and [[liver]] [[Metastasis|metastases]]. [[Brain]] [[Magnetic resonance imaging|MRI]] may be considered for the [[diagnosis]] of [[Metastasis|metastatic]] [[Lesion|lesions]] in [[Patient|patients]] who have been [[Diagnosis|diagnosed]] with [[Cancer staging|stage]] IA-IV melanoma and for [[Prevention (medical)|secondary prevention]] of melanoma in [[Patient|patients]] who were previously [[Diagnosis|diagnosed]] with [[Cancer staging|stage]] IIB-IV melanoma (annually for 5 years). | |||
==MRI== | |||
*[[Magnetic resonance imaging|MRI]] can be useful in the [[Cancer staging|staging]] of [[brain]] and [[liver]] [[Metastasis|metastases]].<ref name="PerngMarcus2015">{{cite journal|last1=Perng|first1=Powell|last2=Marcus|first2=Charles|last3=Subramaniam|first3=Rathan M.|title=18F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis|journal=American Journal of Roentgenology|volume=205|issue=2|year=2015|pages=259–270|issn=0361-803X|doi=10.2214/AJR.14.13575}}</ref><ref name="NanniFantini2010">{{cite journal|last1=Nanni|first1=C.|last2=Fantini|first2=L.|last3=Nicolini|first3=S.|last4=Fanti|first4=S.|title=Non FDG PET|journal=Clinical Radiology|volume=65|issue=7|year=2010|pages=536–548|issn=00099260|doi=10.1016/j.crad.2010.03.012}}</ref> | |||
*[[Malignant]] melonoma on [[Magnetic resonance imaging|MRI]] can present as an enhancing [[mass]] with low to intermediate signal intensity and a high-signal intensity.<ref name="pmid28573265">{{cite journal |vauthors=Ogura I, Sasaki Y, Kameta A, Sue M, Oda T |title=A Rare Case of Malignant Melanoma of the Mandible:
CT and MRI Findings |journal=Chin J Dent Res |volume=20 |issue=2 |pages=111–114 |date=2017 |pmid=28573265 |doi=10.3290/j.cjdr.a38276 |url=}}</ref> | |||
*[[Magnetic resonance imaging|MRI]] can also show regional [[lymphadenopathy]] in [[malignant]] melanoma.<ref name="pmid28573265">{{cite journal |vauthors=Ogura I, Sasaki Y, Kameta A, Sue M, Oda T |title=A Rare Case of Malignant Melanoma of the Mandible:
CT and MRI Findings |journal=Chin J Dent Res |volume=20 |issue=2 |pages=111–114 |date=2017 |pmid=28573265 |doi=10.3290/j.cjdr.a38276 |url=}}</ref> | |||
*[[Brain]] [[MRI]] is recommended for the [[diagnosis]] of [[Metastasis|metastatic]] [[Lesion|lesions]] in the following conditions:<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | |||
:*In [[Patient|patients]] who have been [[Diagnosis|diagnosed]] with [[Cancer staging|stage]] IA-IV melanoma | |||
:*For [[Prevention (medical)|secondary prevention]] of melanoma in [[Patient|patients]] who were previously [[Diagnosis|diagnosed]] with [[Cancer staging|stage]] IIB-IV melanoma (annually for 5 years) | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WikiDoc Help Menu}} | |||
[[Category: | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Medicine]] | |||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Surgery]] | |||
Latest revision as of 18:52, 4 January 2019
|
Melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Melanoma MRI On the Web |
|
American Roentgen Ray Society Images of Melanoma MRI |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
Overview
MRI can be useful in the staging of brain and liver metastases. Brain MRI may be considered for the diagnosis of metastatic lesions in patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma in patients who were previously diagnosed with stage IIB-IV melanoma (annually for 5 years).
MRI
- MRI can be useful in the staging of brain and liver metastases.[1][2]
- Malignant melonoma on MRI can present as an enhancing mass with low to intermediate signal intensity and a high-signal intensity.[3]
- MRI can also show regional lymphadenopathy in malignant melanoma.[3]
- Brain MRI is recommended for the diagnosis of metastatic lesions in the following conditions:[4]
References
- ↑ Perng, Powell; Marcus, Charles; Subramaniam, Rathan M. (2015). "18F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis". American Journal of Roentgenology. 205 (2): 259–270. doi:10.2214/AJR.14.13575. ISSN 0361-803X.
- ↑ Nanni, C.; Fantini, L.; Nicolini, S.; Fanti, S. (2010). "Non FDG PET". Clinical Radiology. 65 (7): 536–548. doi:10.1016/j.crad.2010.03.012. ISSN 0009-9260.
- ↑ 3.0 3.1 Ogura I, Sasaki Y, Kameta A, Sue M, Oda T (2017). "A Rare Case of Malignant Melanoma of the Mandible: CT and MRI Findings". Chin J Dent Res. 20 (2): 111–114. doi:10.3290/j.cjdr.a38276. PMID 28573265.
- ↑ Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.